Business Context and Reporting Period
This Form 8-K Current Report from Assembly Biosciences, Inc. (ASMB) covers events occurring on June 5, 2025, specifically the Company's Annual Meeting of Stockholders. The filing details the approval of amendments to equity incentive plans and a change in the Company's principal financial officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance, equity plan amendments, and personnel appointments.
Material Changes and Corporate Actions
Equity Plan Amendments
- 2018 Stock Incentive Plan (Amendment No. 1): Stockholders approved increasing the share reserve from 1,103,333 to 1,478,333 shares (an increase of 375,000 shares).
- 2018 Stock Incentive Plan (Amendment No. 2): Stockholders approved reserving an additional 225,000 shares specifically for a broad-based supplemental retention grant program with performance-based vesting.
- Employee Stock Purchase Plan (ESPP Amendment No. 1): Stockholders approved increasing the share reserve from 164,500 to 225,000 shares.
Management Change
- Principal Financial Officer (CFO): Jeanette M. Bjorkquist was appointed as the new CFO, succeeding Jason A. Okazaki.
- Continuity: Jason A. Okazaki continues to serve as the Company's Principal Executive Officer (CEO).
- Background: Ms. Bjorkquist has been with the Company since 2019, most recently serving as VP, Finance since June 2025.
Stockholder Vote Results
- Director Elections: All 11 director nominees were elected. Vote counts varied, with the highest support for Tomas Cihlar, Ph.D. (3,722,875 votes for) and the lowest for William R. Ringo, Jr. (2,948,777 votes for).
- Executive Compensation: Ratified on a non-binding advisory basis (2,975,064 for; 784,522 against).
- Independent Auditor: Ernst & Young LLP was ratified for the fiscal year ending December 31, 2025 (4,645,810 for; 8,218 against).
Guidance, Outlook, and Risks
The filing does not provide financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard disclosures regarding the equity plan amendments and the appointment of the new CFO. The text notes there are no family relationships or undisclosed arrangements regarding Ms. Bjorkquist's appointment.
Investor Verification Checklist
- Verify the total number of shares now reserved under the 2018 Stock Incentive Plan (1,478,333 + 225,000 = 1,703,333 total reserved).
- Review the specific vesting terms of the new 225,000-share retention grant program in the Proxy Statement (Appendix C).
- Confirm the transition timeline and responsibilities between the outgoing and incoming CFO.
- Monitor the "Against" vote percentages for directors, particularly William R. Ringo, Jr. and Anthony E. Altig, which exceeded 20% of votes cast.